Imperial Bioscience

Imperial BioScience: Pioneering Tomorrow's Healthcare Solutions Today Imperial BioScience, situated at the heart of innovation in London, is at the forefront of biotechnological advancement, merging cutting-edge science with practical healthcare applications. Founded in 2016, the company has swiftly ascended as a leader in the development and commercialisation of sophisticated microneedle patch technology. At Imperial BioScience, we harness the transformative power of microneedle technology to revolutionize drug delivery systems, enhance patient care, and overcome the limitations of traditional medicinal practices. Our patented microneedle patch therapy (MPT), a hallmark of innovation, enables the delivery of therapeutics directly through the skin's outer layers, promising a future where treatments for chronic diseases like Alzheimer's, Parkinson's, and diabetes are more effective and less invasive. With a robust portfolio of cosmeceutical products (Luna MicroCare) and a burgeoning pipeline of medical-grade therapeutics, Imperial BioScience is dedicated to improving quality of life through its groundbreaking research. Our commitment to excellence, patient-centered innovation, and strategic partnerships positions us to not only lead but transform the healthcare landscape. Discover more about how Imperial Bioscience Ltd is shaping the future of medicine at